SN-38 was obtained from Seqchem (Pangbourne, UK). Irinotecan for in vivo studies was purchased from Hospira (Lake City, IL). Clinical grade mouse monoclonal antibody (mAb) 3F8 was made under the supervision of Dr. Nai-Kong V. Cheung at Memorial Sloan Kettering Cancer Center (MSKCC, New York, NY) [19 (link)]. Murine IgG3 (purified immunoglobulin from murine myeloma, clone DX), bovine serum albumin (BSA), 2-hydroxypropyl-β-cyclodextrin (HPBCD), polyvinyl alcohol (PVA, weight-molecular weight (Mw) 30–70 kDa), 2-(N-morpholino)ethanesulfonic acid (MES) buffer, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide (NHS), 3,6-dimethyl-1,4-dioxane-2,5-dione (D,L-lactide), tin(II) octanoate, anhydrous acetate, phosphate buffered saline (PBS) tablets, sodium hydroxide (NaOH) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). Tetrahydrofuran (THF) was from Chen Samuel Chemicals (Haifa, Israel). Glacial acetic acid, triethylamine (TEA), ethyl acetate (EtOAc), di-sodium tetra-borate 10-hydrate and N,N-dimethylformamide (DMF) were from Panreac (Barcelona, Spain). Water was from Milli-Q water purification system (Millipore, Bedford, MA). Heterobifunctional carboxymethyl-polyethylene glycol (HO-PEG-COOH, Mw 3.4 kg/mole) was from Laysanbio (Arab, AL). Reagents for cell culture were from Life Technologies (Grand Island, NY).
Irinotecan
Manufactured by Pfizer
Sourced in United States
Irinotecan is a laboratory reagent used for research purposes. It is a topoisomerase I inhibitor, a class of compounds that target the enzyme topoisomerase I, which is involved in the regulation of DNA topology. Irinotecan is used in various in vitro and in vivo studies to investigate the effects of topoisomerase I inhibition on cellular processes and biological systems.
Automatically generated - may contain errors
Lab products found in correlation
Docetaxel, by Pfizer (3 mentions)
Epirubicin, by Pfizer (2 mentions)
Paclitaxel, by Pfizer (2 mentions)
Cisplatin, by Pfizer (2 mentions)
Oxaliplatin, by Sanofi (2 mentions)
T dm1, by Roche (2 mentions)
Docetaxel, by Sanofi (2 mentions)
Carboplatin, by Teva Pharmaceuticals (2 mentions)
2 n morpholino ethanesulfonic acid mes buffer, by Merck Group (1 mentions)
Glacial acetic acid, by ITW Reagents (1 mentions)
Phosphate buffered saline tablet, by Merck Group (1 mentions)
Bovine serum albumin (bsa), by Merck Group (1 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)
Sodium hydroxide (naoh), by Merck Group (1 mentions)
Polyvinyl alcohol (pva), by Merck Group (1 mentions)
Milli q water purification system, by Merck Group (1 mentions)
N n dimethylformamide (dmf), by ITW Reagents (1 mentions)
3 6 dimethyl 1 4 dioxane 2 5 dione d l lactide, by Merck Group (1 mentions)
2 hydroxypropyl β cyclodextrin, by Merck Group (1 mentions)
1 ethyl 3 3 dimethylaminopropyl carbodiimide hydrochloride edc, by Merck Group (1 mentions)
18 protocols using irinotecan
1
Synthesis and Characterization of SN-38-loaded Polymeric Nanoparticles
2
Investigating Combination Therapy Efficacy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
APR-246 and GS-MQ were provided by Aprea Therapeutics (Solna, Sweden). Cisplatin, 5-fluorouracil, epirubicin, irinotecan and paclitaxel were from Hospira. GSH-MEE was from Cayman Chemicals. 2-merceptoethanol and H2O2 were from Merck. Erastin was from SelleckChem. GSH, NAC, trolox, ferrostatin-1, Q-VD, DFO and SAS were from Sigma-Aldrich.
3
NSCLC Cell Lines and Chemotherapeutics Handling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The NSCLC cell lines A549, H460, H1703, and H358 were obtained directly from Dr. John Minna's laboratory (Dallas, TX) and maintained at 37°C and 5% CO2 in RPMI 1640 (Gibco) supplemented with 2 mM L-glutamine (Gibco) and 10% fetal bovine serum (Gibco). Human Bronchial Epithelial Cells (Cell Applications) were maintained in Bronchial/Tracheal Epithelial Growth Medium (Cell Applications) at 37°C and 5% CO2. HBEpC cells beyond passage 3 were not used for experiments. PAPSS1 (1:1000) primary antibody was obtained from Abcam while β-Actin (1:50000), cleaved caspase-3 (1:1000), Cyclin A2 (1:2000), Cyclin E1 (1:1000), and cleaved PARP (1:1000) primary antibodies were purchased from Cell Signaling Technology. The chemotherapeutics cisplatin, carboplatin, irinotecan, topotecan, and docetaxel were obtained as ready-to-inject solutions from Hospira. Epirubicin and doxorubicin were obtained from Pfizer while oxaliplatin and mitomycin C were purchased from Sanofi Aventis and Novopharm respectively.
4
Combination Anticancer Drug Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
T‐DM1 and S‐methyl DM1 were kindly provided by Roche and ImmunoGen, respectively. Pertuzumab and cisplatin were purchased from Mylan. Trastuzumab was purchased from Virbac. Afatinib, vinorelbine, and lapatinib were purchased from Vidal. Fluorouracil and doxorubicin were purchased from Accord Healthcare. DM1 (emtansine) and colchicine were purchased from Abcam and Sigma, respectively. Paclitaxel and vincristine were purchased from Bristol Myers and Teva, respectively. Irinotecan was purchased from Hospira. PNU‐159682 was kindly provided by Mablink Bioscience.
5
Chemosensitivity of Ascites-Derived PDAC Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
2 × 103 ascites-derived PDAC primary cells per well from 14 different patients were seeded in 96-well plates and cultured for 3–4 days. The cells were treated with different chemotherapeutic agents: gemcitabine 10 μM (Medac, Wedel, Germany), erlotinib 10 μM (Roche, Basel, Switzerland), cisplatin 1 μM (Pharma-Chem, Haarlem, Holland), 5FU 5 μM and oxaliplatin 6 μM (Ebewe, Unterach, Austria), irinotecan 10 μM (Hospira, Melbourne, Australia) and paclitaxel 1 μM (Teva, Petach Tikva, Israel) for 72 h. FOLFIRINOX is a combination of 5FU, irinotecan and oxaliplatin. Cell proliferation was measured using the XTT cell proliferation kit (Biological Industries) according to the manufacturer's protocol.
6
Chemotherapeutic Agents Preparation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Se-methylselenocysteine was purchased from Sigma (St Louis, MO, USA) and dissolved in sterile saline (0.9% NaCl) at a concentration of 1 mg ml−1. Cyclophosphamide and CDDP (Bristol-Myers Squibb Co., Princeton, NJ, USA) were used as a ready-to-use clinical formulation solution in 50–100 ml vials that contained 1000 mg of CTX (20 mg ml) and 100 mg of CDDP (1 mg ml−1), respectively. Oxaliplatin (ELOXATIN) was purchased from Sanofi-Synthelabo (New York, NY, USA) as a solution of 5 mg ml−1 in 10 ml vials. Irinotecan was purchased from Pfizer Inc. (New York, NY, USA) as a ready-to-use clinical formulation solution in 5 ml vials containing 100 mg of the drug (20 mg ml−1).
7
Establishment and Characterization of RMS Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Ba/F3 TEL-FGFR4, a murine hematopoietic cell line that expresses a constitutively active FGFR4 kinase domain [19 (link)], was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1% penicillin/streptomycin, and 1.5 ug/mL puromycin. RMS559 is a FN RMS cell line with an FGFR4V550L activating mutation; RH4 and SCMC are FP RMS cell lines with FGFR4 overexpression; and 7250 is a normal human fibroblast cell line. These cell lines were grown in DMEM medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin. All cell lines were STR profiled and negative for mycoplasma. Futibatinib was obtained through a Cooperative Research and Development Agreement (CRADA) with Taiho Oncology (Princeton, NJ, USA). Irinotecan (752903, Pfizer, New York, NY, USA) and Vincristine (030906, Pfizer) were obtained through the NIH Division of Veterinary Resources Pharmacy.
8
Weekly Docetaxel and Irinotecan Regimen
9
Weekly Docetaxel and Irinotecan Regimen
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Docetaxel (35 mg/m2) (Sanofi-Aventis) was administered intravenously over 60 minutes. After the completion of the Docetaxel infusion, irinotecan (Pfizer) was administered intravenously over 30 minutes at a dose of 50 mg/m2. Chemotherapy was administered once a week (days 1, 8, 15, and 22) for 4 consecutive weeks followed by 2 weeks rest. This constituted a cycle of treatment.
10
Tarextumab and Chemotherapy in Allograft Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NOD/SCID mice implanted with OMP-LU66 or TKO allografts were randomized and treated with a control antibody or tarextumab (OMP-59R5, 40mg/kg, Q2W) as a single agent or in combination with the chemotherapy agents carboplatin (25 mg/kg, QW, Teva) and irinotecan (25 mg/kg, QW, Pfizer). We used carboplatin and irinotecan (instead of cisplatin and etoposide) for these longer term studies as they are less toxic, better tolerated by the mice, and have been shown to have similar efficacies as cisplatin and etoposide36 (link),37 (link). To avoid the side effects of total Notch pathway inhibition in vivo38 (link),39 (link), we sought to reduce Notch signaling with the Notch2/3 antagonist tarextumab. After approximately four cycles, chemotherapy was discontinued and tarextumab dosing was continued until study completion. Mice with tumor volumes at or exceeding the 2500mm3 (link) limit permitted by the IACUC were sacrificed regardless of timepoint.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!